Victory Capital Management
AQST icon

Victory Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Victory Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.9K Buy
13,682
+505
+4% +$2.13K ﹤0.01% 2385
2026
Q1 		$54.7K Buy
13,177
+21
+0.2% +$85 ﹤0.01% 2309
2025
Q4 		$85K Buy
13,156
+362
+3% +$2.26K ﹤0.01% 2284
2025
Q3 		$71.5K Buy
12,794
+1,862
+17% +$8.05K ﹤0.01% 2320
2025
Q2 		$36.2K Buy
10,932
+364
+3% +$1.04K ﹤0.01% 2407
2025
Q1 		$30.6K Buy
+10,568
New +$32K ﹤0.01% 2402
2024
Q4 		– Sell
-10,073
Closed -$50.2K – 2474
2024
Q3 		$50.2K Sell
10,073
-226
-2% -$879 ﹤0.01% 2392
2024
Q2 		$26.8K Buy
+10,299
New +$34.4K ﹤0.01% 2408
2020
Q2 		– Sell
-4,980
Closed -$11K – 2547
2020
Q1 		$11K Buy
+4,980
New +$18.9K ﹤0.01% 3040
2019
Q4 		– Sell
-3,148
Closed -$10K – 2667
2019
Q3 		$10K Buy
+3,148
New +$11.8K ﹤0.01% 3252
2019
Q2 		– Sell
-5,000
Closed -$35K – 1823
2019
Q1 		$35K Hold
5,000
– – ﹤0.01% 1725
2018
Q4 		$32K Hold
5,000
– – ﹤0.01% 1720
2018
Q3 		$88K Buy
+5,000
New +$82.4K ﹤0.01% 1679

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Victory Capital Management's AQST Position: Q2 2026 in Review

Victory Capital Management increased its Aquestive Therapeutics (AQST) stake by 3.8% in Q2 2026, buying an estimated $2.13K and bringing the position to 13,682 shares worth $56.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2385.

Victory Capital Management first reported a position in AQST in Q3 2018 and has held it in 13 quarters since. The position peaked at $88K in Q3 2018. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Victory Capital Management held 13,682 shares of Aquestive Therapeutics worth $56.9K as of Q2 2026.
  • Victory Capital Management bought 505 Aquestive Therapeutics shares in Q2 2026, an estimated $2.13K.
  • Aquestive Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2385 holding.
  • Victory Capital Management first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 13 quarters since.
  • Victory Capital Management's Aquestive Therapeutics position peaked at $88K in Q3 2018.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.